Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344831 | 0.85 | DDB1 (0.39) | MEN1KMT2AMAPTALDH1A1ESR2 | |
| SCHEMBL4875412 | 0.81 | DDB1 (0.42) | MEN1KMT2AMAPTALDH1A1ESR2 | |
| SCHEMBL1583540 | 0.81 | CNR2 (0.40) | MAPTALDH1A1ESR2USP2SMN1; SMN2 | |
| SCHEMBL22593100 | 0.80 | NR1H2 (0.38) | MEN1KMT2AMAPTALDH1A1ESR2 | |
| SCHEMBL1343264 | 0.78 | HRH3 (0.42) | MEN1KMT2AHPGDESR2USP2 | |
| SCHEMBL18205300 | 0.77 | NR1H2 (0.39) | MEN1KMT2AMAPTALDH1A1ESR2 | |
| SCHEMBL7982635 | 0.77 | NR1H2 (0.40) | MEN1KMT2AMAPTALDH1A1ESR2 | |
| SCHEMBL17691085 | 0.77 | DDB1 (0.41) | MEN1KMT2AMAPTALDH1A1ESR2 | |
| SCHEMBL24072420 | 0.76 | PLA2G2A (0.44) | MAPTALDH1A1ESR2USP2SMN1; SMN2 | |
| SCHEMBL21520542 | 0.76 | DDB1 (0.39) | MEN1KMT2AMAPTALDH1A1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094778-B2 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1289965-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-6818645-B2 | 2-AMINO-TRIHYDROINDOLE OR TETRAHYDRONAPTHALENE-2-YL DERIVATIVES, USEFUL FOR DISEASE STATE ASSOCIATED WITH SMOOTH MUSCLE DISORDERS, SUCH AS GASTROINTESTINAL AND UROGENITAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-16 | — | — | US | disclosed |
| EP-1289964-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | DVORAK CHARLES ALOIS (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040034018-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | WEIKERT ROBERT JAMES (US) | 2004-02-19 | — | — | US | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| US-6645958-B2 | Oxazepine derivatives; urogenital, gastrointestinal, and respiratory system disorders; antiasthmatic and antiallergen agents | SYNTEX (U.S.A.) LLC | 2003-11-11 | — | — | US | disclosed |
| US-20030109524-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | WEIKERT ROBERT JAMES (US) | 2003-06-12 | — | — | US | disclosed |
| EP-1289964-A1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| US-6500822-B2 | MUSCULAR DISORDERS, GASTROINTESTINAL DISORDERS, RESPIRATORY SYSTEM DISORDERS | SYNTEX (U.S.A.) LLC | 2002-12-31 | — | — | US | disclosed |
| US-20020004494-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
| WO-2001090082-A1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004494-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM4 | MEN1 2577/4885KMT2A 1832/4885MAPT 3997/4885 |
| US-20030109524-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM4 | MEN1 2577/4885KMT2A 1832/4885MAPT 3997/4885 |
| US-20040034018-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM4 | MEN1 2577/4885KMT2A 1832/4885MAPT 3997/4885 |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | MEN1 1954/4885KMT2A 1941/4885MAPT 4142/4885 |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | MEN1 1892/4885KMT2A 2014/4885MAPT 4292/4885 |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | MEN1 1892/4885KMT2A 2014/4885MAPT 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.